An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …

New treatment strategies have substantially changed the course of rheumatoid arthritis.
Many patients can achieve remission if the disease is recognised early and is treated …

Objective. To revise the current juvenile idiopathic arthritis (JIA) International League of
Associations for Rheumatology (ILAR) classification criteria with an evidence-based …

Summary Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor,
showed efficacy in combination with stable background conventional synthetic disease …

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in
2012, but the evidence for these recommendations was only of indirect nature. These …

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

Background Different diagnostic and classification criteria are available for hereditary
recurrent fevers (HRF)—familial Mediterranean fever (FMF), tumour necrosis factor receptor …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic …